Drugs / Evixapodlin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04049617 | Aug 2019 → Mar 2021 | cancer | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evixapodlin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04049617 ↗ |
| Known as | GS-4224 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095237 ↗ |
| Modality | Small molecule | — CHEMBL5095237 ↗ |